Loading article...
Loading article...
Stream/Area:
-
Subject:
-
Paper ID:
IJSREM51454
Volume:
9 |
7 |
Jul 2025
Pages:
Publication Frequency:
Monthly (12 issues per year)
License:International Journal of Scientific Research in Engineering and Management follows the Creative Commons Attribution 4.0 (CC BY 4.0) License, allowing free use and distribution with proper attribution.
Non–small cell lung cancer (NSCLC) is a highly virulent type of cancerous illness globally due to the restriction on its early diagnosis and prognosis prediction of disease. Therefore, in this paper, we present an innovative radio genomic model, which synergistically integrates CT-image-based radiomic features and mutational profiles in circulating tumor DNA (ctDNA) to enhance diagnosis capacity and prognosis prediction of NSCLC. We enrolled 200 high-risk patients in three hospitals for contrast-enhanced CT scan and blood test comparison between baseline of any treatment trial. We extracted 1,200 radiomic features of intensity, texture, and tumor region shape after segmentation on the CT scan. Conversely, ctDNA were analyzed via top 52 most frequently mutated lung cancer genes targeted sequencing. To train our model, we used the LASSO feature selection algorithm and trained a random forest classifier on an initial training set of 140 patients and cross-validated the model in a second set of 60. The AUC of the hybrid model was a whopping 0.93 (95% CI, 0.89–0.97) distinguishing between early- stage NSCLC and benign nodules—compared with models built using radiomics alone (AUC 0.82) or ctDNA alone (AUC 0.79). Sensitivity was 91% and specificity was 87% at the cut-point when the decision was most optimizing the plot. Further, patients with increasing model-based risk scores had significantly poorer progression-free survival (hazard ratio 3.7; 95% CI, 2.2–6.1; p < 0.001), adjusting for clinical stage and ECOG performance status. These results make composite imaging and liquid biopsy data an appropriate potentially noninvasive first-line screening test for NSCLC and personalized risk stratification worthy of assessment by large prospective clinical trials.
KEYWORDS
Publication Date
7/19/2025
Peer Review Type
Double-Blind Peer Review
Review Rounds: 2
Documents
Article Views
0
Total views since publication
PDF Downloads
2
Total downloads since publication
Geographic Reach
5
Digital Preservation: This article is permanently archived on Zenodo and complies with all data preservation standards across major indexing platforms.
Plagiarism Screening
This manuscript has been checked for plagiarism using TurnitinPlagiarismChecker software.
Conflict of Interest
The authors declare no conflict of interest related to this research work.
Funding Information
No funding information available for this research.
Related research in the same subject area
Loading similar articles...